{"id":695,"date":"2026-05-14T16:20:41","date_gmt":"2026-05-14T15:20:41","guid":{"rendered":"http:\/\/seamlessbio.de\/?page_id=695"},"modified":"2026-06-27T12:09:09","modified_gmt":"2026-06-27T11:09:09","slug":"biopharma-atmp","status":"publish","type":"page","link":"https:\/\/seamlessbio.de\/de\/biopharma-atmp\/","title":{"rendered":"Application Cell Therapy &amp; ATMP Manufacturing"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"695\" class=\"elementor elementor-695\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d76a24b e-con e-atomic-element e-flexbox-base e-c01055a \" data-id=\"d76a24b\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"d76a24b\">\n    \t\t<div class=\"elementor-element elementor-element-dbe85ef elementor-widget elementor-widget-html\" data-id=\"dbe85ef\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<!-- YOAST SEO SETTINGS\nSlug:             applications\/cell-therapy-atmps\nFocus Keyword:    cell therapy ATMP FBS human serum hPL GMP manufacturing\nSEO Title (EN):   Cell Therapy & ATMP Manufacturing \u2014 FBS, Human Serum & hPL Guide | SeamlessBio\nMeta Desc (EN):   Complete reagent guide for ATMP and cell therapy manufacturing. FBS Tet-Free, Ultra Low IgG, Human Serum AB OTC Male, hPL. Batch reservation, EU supply, EMA\/410\/01 compliant. SeamlessBio.\nTitle length:     87 chars\nDesc length:      218 chars\n-->\n<section class=\"sb-atmp\">\n<style>\n.sb-atmp,.sb-atmp *,.sb-atmp *::before,.sb-atmp *::after{box-sizing:border-box;}\n.sb-atmp{background:#fff;padding:70px 40px 90px;font-family:Arial,sans-serif;color:#202020;}\n.sb-atmp .wrap{max-width:1200px;width:100%;margin:0 auto;}\n.sb-atmp .bc{display:flex;flex-wrap:wrap;gap:8px;margin:0 0 24px;color:#777;font-size:14px;}\n.sb-atmp .bc a{color:#18b7b2!important;text-decoration:none!important;font-weight:700;}\n.sb-atmp .bc strong{color:#111;font-weight:800;}\n.sb-atmp .hero{padding:64px 56px;margin-bottom:48px;border-radius:30px;background:linear-gradient(135deg,#18b7b2 0%,#65d3cf 52%,#e9fbfa 100%);color:#fff;}\n.sb-atmp .hero .ey{display:inline-block;margin-bottom:14px;font-size:13px;font-weight:900;text-transform:uppercase;letter-spacing:1.8px;}\n.sb-atmp .hero h1{margin:0 0 18px;color:#fff;font-size:clamp(26px,3.2vw,40px);line-height:1.1;font-weight:900;letter-spacing:-1px;max-width:840px;}\n.sb-atmp .hero .sub{max-width:720px;margin:0 0 30px;color:#fff;font-size:17px;line-height:1.65;}\n.sb-atmp .hbtns{display:flex;flex-wrap:wrap;gap:14px;}\n.sb-atmp .btn1{display:inline-flex;align-items:center;justify-content:center;min-height:46px;padding:0 28px;border-radius:999px;background:#18b7b2;color:#fff!important;text-decoration:none!important;text-transform:uppercase;font-size:13px;font-weight:900;letter-spacing:.6px;transition:all .25s;}\n.sb-atmp .btn1:hover{background:#139b97;transform:translateY(-2px);}\n.sb-atmp .btn2{display:inline-flex;align-items:center;justify-content:center;min-height:46px;padding:0 28px;border-radius:999px;background:transparent;border:2px solid #fff;color:#fff!important;text-decoration:none!important;text-transform:uppercase;font-size:13px;font-weight:900;letter-spacing:.6px;transition:all .25s;}\n.sb-atmp .btn2:hover{background:#fff;color:#139b97!important;transform:translateY(-2px);}\n.sb-atmp .warn{background:rgba(245,166,35,.1);border-left:4px solid #f5a623;border-radius:8px;padding:18px 22px;margin-bottom:32px;font-size:14px;color:#444;line-height:1.7;}\n.sb-atmp .warn strong{color:#111;display:block;margin-bottom:6px;font-size:15px;}\n.sb-atmp .note{background:rgba(24,183,178,.08);border-left:4px solid #18b7b2;border-radius:8px;padding:18px 22px;margin-bottom:32px;font-size:14px;color:#444;line-height:1.7;}\n.sb-atmp .note strong{color:#111;display:block;margin-bottom:6px;font-size:15px;}\n.sb-atmp .cards{display:grid;grid-template-columns:repeat(4,1fr);gap:22px;margin-bottom:48px;}\n.sb-atmp .card{min-height:210px;padding:28px;border-radius:24px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);transition:all .25s;}\n.sb-atmp .card:hover{background:#18b7b2;color:#fff;transform:translateY(-6px);box-shadow:0 18px 40px rgba(24,183,178,.22);}\n.sb-atmp .card .num{display:inline-flex;margin-bottom:24px;color:#18b7b2;font-size:13px;font-weight:900;}\n.sb-atmp .card:hover .num{color:#fff;}\n.sb-atmp .card h3{margin:0 0 12px;color:inherit;font-size:18px;line-height:1.3;font-weight:900;}\n.sb-atmp .card p{margin:0;color:inherit;font-size:14px;line-height:1.6;opacity:.88;}\n.sb-atmp .two{display:grid;grid-template-columns:1.1fr 0.9fr;gap:34px;margin-bottom:34px;}\n.sb-atmp .two>div{padding:34px;border-radius:26px;background:#fff;border:1px solid #eee;}\n.sb-atmp .two h2{margin:0 0 14px;color:#111;font-size:24px;font-weight:900;}\n.sb-atmp .two h3{margin:0 0 14px;color:#111;font-size:20px;font-weight:900;}\n.sb-atmp .two p{margin:0 0 12px;color:#555;font-size:15px;line-height:1.7;}\n.sb-atmp .two ul{margin:0;padding:0;list-style:none;}\n.sb-atmp .two li{position:relative;padding:10px 0 10px 22px;border-bottom:1px solid #eee;color:#555;font-size:14px;line-height:1.5;}\n.sb-atmp .two li::before{content:\"\";position:absolute;left:0;top:18px;width:8px;height:8px;border-radius:50%;background:#18b7b2;}\n.sb-atmp .two li a{color:#139b97!important;font-weight:700;text-decoration:none!important;}\n.sb-atmp .two li a:hover{text-decoration:underline!important;}\n.sb-atmp .sec{margin-bottom:34px;padding:34px;border-radius:26px;background:#fff;border:1px solid #eee;}\n.sb-atmp .sec h2{margin:0 0 14px;color:#111;font-size:22px;font-weight:900;}\n.sb-atmp .sec p{margin:0 0 12px;color:#555;font-size:15px;line-height:1.7;}\n.sb-atmp .tw{overflow-x:auto;margin-top:16px;}\n.sb-atmp table{width:100%;border-collapse:collapse;font-size:14px;min-width:480px;}\n.sb-atmp thead th{background:#18b7b2;color:#fff;padding:11px 13px;text-align:left;font-weight:700;}\n.sb-atmp tbody tr:nth-child(even){background:#f5fffe;}\n.sb-atmp tbody tr:hover{background:#e8f9f8;}\n.sb-atmp tbody td{padding:10px 13px;vertical-align:top;border-bottom:1px solid #e5e5e5;line-height:1.5;font-size:13px;}\n.sb-atmp table a{color:#18b7b2;text-decoration:none;font-weight:600;}\n.sb-atmp table a:hover{color:#139b97;}\n.sb-atmp .faq{margin-bottom:34px;padding:34px;border-radius:26px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);}\n.sb-atmp .faq h2{margin:0 0 20px;color:#111;font-size:22px;font-weight:900;}\n.sb-atmp .faq-item{border-bottom:1px solid #e0e0e0;padding:18px 0;}\n.sb-atmp .faq-item:last-child{border-bottom:none;padding-bottom:0;}\n.sb-atmp .faq-q{font-size:15px;font-weight:900;color:#111;margin-bottom:8px;}\n.sb-atmp .faq-a{font-size:14px;color:#555;line-height:1.7;}\n.sb-atmp .related{margin-bottom:34px;padding:28px 34px;border-radius:26px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);}\n.sb-atmp .related h3{margin:0 0 16px;color:#111;font-size:18px;font-weight:900;}\n.sb-atmp .rel-grid{display:grid;grid-template-columns:repeat(2,1fr);gap:12px;}\n.sb-atmp .rel-grid a{display:flex;align-items:center;min-height:50px;padding:12px 16px;border-radius:12px;background:#fff;border:1px solid #e0e0e0;color:#111!important;text-decoration:none!important;font-size:13px;font-weight:700;transition:all .2s;}\n.sb-atmp .rel-grid a:hover{border-color:#18b7b2;color:#139b97!important;}\n.sb-atmp .cta{margin-top:16px;padding:54px 34px;border-radius:30px;background:#f7fbfb;border:1px solid rgba(24,183,178,.18);text-align:center;}\n.sb-atmp .cta h2{margin:0 0 12px;color:#111;font-size:28px;font-weight:900;}\n.sb-atmp .cta p{max-width:760px;margin:0 auto 26px;color:#555;font-size:15px;line-height:1.65;}\n.sb-atmp .ctabtns{display:flex;flex-wrap:wrap;gap:14px;justify-content:center;}\n.sb-atmp .ctab1,.sb-atmp .ctab2{display:inline-flex;align-items:center;justify-content:center;min-height:46px;padding:0 28px;border-radius:999px;font-size:13px;font-weight:900;text-transform:uppercase;letter-spacing:.6px;text-decoration:none!important;transition:all .25s;}\n.sb-atmp .ctab1{background:#18b7b2;color:#fff!important;}\n.sb-atmp .ctab1:hover{background:#139b97;transform:translateY(-2px);}\n.sb-atmp .ctab2{background:transparent;border:2px solid #18b7b2;color:#18b7b2!important;}\n.sb-atmp .ctab2:hover{background:#18b7b2;color:#fff!important;transform:translateY(-2px);}\n@media(max-width:1100px){\n  .sb-atmp .hero{padding:48px 36px;}\n  .sb-atmp .cards{grid-template-columns:repeat(2,1fr);}\n  .sb-atmp .two{grid-template-columns:1fr;}\n  .sb-atmp .rel-grid{grid-template-columns:1fr;}\n}\n@media(max-width:700px){\n  .sb-atmp{padding:50px 16px 70px;}\n  .sb-atmp .hero{padding:40px 24px;border-radius:24px;}\n  .sb-atmp .hero h1{font-size:25px;}\n  .sb-atmp .hbtns{flex-direction:column;}\n  .sb-atmp .btn1,.sb-atmp .btn2{width:100%;}\n  .sb-atmp .cards{grid-template-columns:1fr;}\n  .sb-atmp .card{min-height:auto;padding:20px;}\n  .sb-atmp .two>div,.sb-atmp .sec,.sb-atmp .faq{padding:20px;}\n  .sb-atmp .cta{padding:36px 20px;}\n  .sb-atmp .ctabtns{flex-direction:column;}\n  .sb-atmp .ctab1,.sb-atmp .ctab2{width:100%;}\n}\n<\/style>\n\n<div class=\"wrap\">\n  <div class=\"bc\">\n    <a href=\"http:\/\/seamlessbio.de\/\">Home<\/a><span>\/<\/span>\n    <a href=\"https:\/\/www.seamlessbio.de\/applications\/\">Applications<\/a><span>\/<\/span>\n    <strong>Cell Therapy &amp; ATMP Manufacturing<\/strong>\n  <\/div>\n\n  <div class=\"hero\">\n    <span class=\"ey\">SeamlessBio \u2014 Solutions by Application<\/span>\n    <h1>Cell Therapy &amp; ATMP Manufacturing \u2014 FBS, Human Serum &amp; hPL Supply Guide<\/h1>\n    <p class=\"sub\">Advanced therapy medicinal products \u2014 CAR-T cells, iPSC-derived therapies, gene-modified cell products \u2014 place exceptionally high demands on biological raw materials. Serum lots must be pre-screened and reserved months in advance, endotoxin must be minimal, and tetracycline-free grades are mandatory for inducible expression systems. SeamlessBio supplies specialty FBS, human serum, hPL and bioprocessing bags for ATMP manufacturing with EU supply chain, batch reservation, and full EMA documentation.<\/p>\n    <div class=\"hbtns\">\n      <a href=\"https:\/\/www.seamlessbio.de\/about-us\/contact-imprint\/\" class=\"btn1\">Contact Us<\/a>\n      <a href=\"https:\/\/shop.seamlessbio.de\" class=\"btn2\">View in Shop<\/a>\n    <\/div>\n  <\/div>\n\n  <div class=\"warn\">\n    <strong>\u26a0 EMA\/410\/01 \u2014 The Regulatory Baseline for Serum in ATMP Manufacturing:<\/strong>\n    EMA guideline EMA\/410\/01 explicitly discourages the use of FBS in the manufacture of ATMPs including CAR-T cell products. <strong>Human serum is the preferred ancillary material.<\/strong> Ph. Eur. 5.2.12 documentation is required for all human-derived ancillary materials in GMP-phase manufacturing. SeamlessBio provides full Ph. Eur. 5.2.12 and Eudralex Vol. 4 Part IV documentation on request. Where FBS is still used (research phase, non-clinical studies), <a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-tet-free\">FBS Tet-Free<\/a>, <a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-ultra-low-igg-low-igg\">Ultra Low IgG<\/a> and <a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">Low Endotoxin<\/a> grades are mandatory \u2014 not standard FBS.\n  <\/div>\n\n  <div class=\"cards\">\n    <div class=\"card\">\n      <span class=\"num\">01<\/span>\n      <h3>Human Serum AB OTC Male<\/h3>\n      <p>GMP gold standard for ex vivo T cell expansion. AB type \u2014 no anti-A\/B agglutination. Male donors \u2014 no hormonal variability. Off-the-clot \u2014 maximum platelet growth factors (PDGF, EGF, TGF-\u03b2). EMA\/410\/01 preferred ancillary material.<\/p>\n    <\/div>\n    <div class=\"card\">\n      <span class=\"num\">02<\/span>\n      <h3>Human Platelet Lysate (hPL)<\/h3>\n      <p>Xeno-free FBS alternative for MSC expansion and T cell culture. No animal-derived components. Higher MSC proliferation rate than FBS. GMP documentation available. EU donor network.<\/p>\n    <\/div>\n    <div class=\"card\">\n      <span class=\"num\">03<\/span>\n      <h3>FBS Tet-Free &lt;10 ng\/mL<\/h3>\n      <p>Mandatory for Tet-On\/Tet-Off inducible CAR construct expression and lentiviral packaging systems. Tetracycline residues at even ng\/mL levels suppress transgene induction \u2014 the most common cause of failed inducible CAR-T constructs.<\/p>\n    <\/div>\n    <div class=\"card\">\n      <span class=\"num\">04<\/span>\n      <h3>FBS Ultra Low IgG &lt;5 \u00b5g\/mL<\/h3>\n      <p>For research-phase T cell activation, ADCC assay development, and flow cytometry readouts. Bovine IgG in standard FBS occupies Fc\u03b3R on T cells and APCs \u2014 directly interfering with CD3\/CD28 activation signals and ADCC measurement.<\/p>\n    <\/div>\n  <\/div>\n\n  <div class=\"two\">\n    <div>\n      <h2>EMA\/410\/01 \u2014 Why Human Serum is the ATMP Standard<\/h2>\n      <p>EMA guideline EMA\/410\/01 (Guidelines on the use of bovine serum in the manufacture of human biological medicinal products) explicitly discourages FBS in clinical ATMP manufacturing. The regulatory concern is twofold: FBS introduces bovine xenogenic antigens that can sensitise expanded T cells and generate anti-bovine immune responses in the patient following infusion, and FBS lot variability introduces process variability that is unacceptable in GMP manufacturing.<\/p>\n      <p><strong>Human Serum AB Male OTC<\/strong> is the gold standard for ex vivo T cell expansion in CAR-T manufacturing. Each specification is mechanistically justified:<\/p>\n      <p><strong>AB type:<\/strong> Prevents anti-A\/B antibody-mediated agglutination and lysis of residual red blood cells in donor T cell expansion cultures \u2014 donor T cells can be any blood group.<\/p>\n      <p><strong>Male donors only:<\/strong> Eliminates hormonal lot-to-lot variability from the female menstrual cycle. Oestrogen and progesterone affect T cell activation thresholds and cytokine production \u2014 introducing expansion yield variation between manufacturing runs.<\/p>\n      <p><strong>Off-the-clot:<\/strong> Preserves maximum platelet-derived growth factors (PDGF, EGF, TGF-\u03b2, IGF-1) released during clot formation. These factors directly amplify T cell activation signals and ex vivo expansion yield. Centrifuged or platelet-poor preparations have significantly lower growth factor content.<\/p>\n      <p>For fully xeno-free protocols, rHSA Premium Grade replaces albumin supplementation and human platelet lysate (hPL) replaces serum entirely for MSC and some T cell expansion applications.<\/p>\n    <\/div>\n    <div>\n      <h3>Key products by ATMP type<\/h3>\n      <ul>\n        <li><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-off-the-clot-type-ab-male\">Human Serum AB OTC Male<\/a> \u2014 CAR-T ex vivo expansion<\/li>\n        <li><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-type-ab-male\">Human Serum AB HI<\/a> \u2014 T cell activation, QC ELISpot<\/li>\n        <li><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-platelet-lysate-hpl\">Human Platelet Lysate (hPL)<\/a> \u2014 Xeno-free MSC, T cell expansion<\/li>\n        <li><a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/rec-human-serum-albumin-rec-hsa\/rhsa-premium-grade\">rHSA Premium Grade<\/a> \u2014 Xeno-free media supplement, cryopreservation<\/li>\n        <li><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-tet-free\">FBS Tet-Free &lt;10 ng\/mL<\/a> \u2014 Inducible CAR, lentiviral packaging<\/li>\n        <li><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-ultra-low-igg-low-igg\">FBS Ultra Low IgG &lt;5 \u00b5g\/mL<\/a> \u2014 Research T cell activation, ADCC<\/li>\n        <li><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">FBS Very Low Endotoxin \u22641 EU\/mL<\/a> \u2014 ELISpot, PBMC potency assays<\/li>\n        <li><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-es-cell-pre-tested\">FBS ES Cell Pre-Tested<\/a> \u2014 iPSC culture, reprogramming<\/li>\n      <\/ul>\n    <\/div>\n  <\/div>\n\n  <!-- KEY REAGENTS TABLE -->\n  <div class=\"sec\">\n    <h2>Key Reagents for ATMP Applications \u2014 Complete Specification Table<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Product<\/th><th>Grade \/ Specification<\/th><th>ATMP Application<\/th><th>Why This Grade<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-off-the-clot-type-ab-male\">Human Serum AB OTC Male<\/a><\/td>\n            <td>Type AB, male donors, off-the-clot, native<\/td>\n            <td>CAR-T, TCR-T, NK cell ex vivo expansion. iPSC-derived T cell products.<\/td>\n            <td>EMA\/410\/01 preferred. Max platelet growth factors. No anti-A\/B. No hormonal variability between lots.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-type-ab-male\">Human Serum AB HI<\/a><\/td>\n            <td>Type AB, heat inactivated 56\u00b0C\/30 min<\/td>\n            <td>T cell activation phase (complement-sensitive protocols). PBMC-based QC potency assays. ELISpot.<\/td>\n            <td>Complement destroyed \u2014 prevents lysis of activated T cells and PBMC during culture and assay.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-platelet-lysate-hpl\">Human Platelet Lysate (hPL)<\/a><\/td>\n            <td>Pooled, pathogen-screened, EU donors<\/td>\n            <td>Xeno-free MSC expansion. T cell expansion where full xeno-free protocol required. GMP-transition preferred FBS alternative.<\/td>\n            <td>No animal-derived components. 3\u20135\u00d7 higher MSC proliferation vs FBS in some protocols. EMA Annex I xeno-free compliant.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/rec-human-serum-albumin-rec-hsa\/rhsa-premium-grade\">rHSA Premium Grade<\/a><\/td>\n            <td>Rice-expressed, \u226599% purity, \u22641 EU\/mg, ISO 13485<\/td>\n            <td>Albumin supplement in defined xeno-free T cell or iPSC media. Formulation buffer for harvest and GMP cryopreservation.<\/td>\n            <td>No donor variability. No blood-borne pathogen risk. Defined composition. GMP documentation package available.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-tet-free\">FBS Tet-Free &lt;10 ng\/mL<\/a><\/td>\n            <td>Tetracycline &lt;10 ng\/mL \u2014 tested per lot<\/td>\n            <td>Tet-On\/Tet-Off inducible CAR construct expression. Lentiviral packaging cell line culture (Tet-regulatable packaging systems). AAV Tet-inducible production.<\/td>\n            <td>Tetracycline at even ng\/mL residues suppress Tet-responsive promoters \u2014 the most common hidden cause of failed inducible transgene expression in CAR-T development.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-ultra-low-igg-low-igg\">FBS Ultra Low IgG &lt;5 \u00b5g\/mL<\/a><\/td>\n            <td>IgG &lt;5 \u00b5g\/mL \u2014 chromatographic depletion<\/td>\n            <td>Research-phase T cell activation screening. ADCC potency assay development. Flow cytometry with Fc-receptor-bearing cells. Hybridoma screening.<\/td>\n            <td>Standard FBS contains 200\u2013800 \u00b5g\/mL bovine IgG that occupies Fc\u03b3R on T cells and APCs \u2014 directly interfering with CD3\/CD28 activation signals and masking ADCC readout.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">FBS Very Low Endotoxin \u22641 EU\/mL<\/a><\/td>\n            <td>\u22641 EU\/mL \u2014 LAL tested per lot<\/td>\n            <td>ELISpot potency assays, PBMC-based release testing, NK cell functional assays, monocyte\/macrophage-sensitive primary cell culture.<\/td>\n            <td>Endotoxin activates monocytes via TLR4 \u2192 non-specific IFN-\u03b3\/TNF-\u03b1 background in ELISpot and multiplex cytokine assays \u2014 masking antigen-specific CAR-T potency signal.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-es-cell-pre-tested\">FBS ES Cell Pre-Tested<\/a><\/td>\n            <td>Oct4\/Sox2\/Nanog validated, &lt;5% spontaneous differentiation per lot<\/td>\n            <td>iPSC reprogramming, feeder-dependent iPSC maintenance, embryoid body formation, hematopoietic differentiation for iPSC-derived CAR-T.<\/td>\n            <td>Standard FBS drives spontaneous iPSC differentiation within 1\u20132 passages \u2014 lot not screened for pluripotency maintenance. ES Cell Pre-Tested lots validated per lot before release.<\/td>\n          <\/tr>\n          <tr>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-gamma-irradiated\">FBS Gamma Irradiated \u226525 kGy<\/a><\/td>\n            <td>Gamma irradiated ISO 11137<\/td>\n            <td>Enhanced viral safety margin for ATMP lentiviral vector production in BSL-2 facilities. Additional pathogen clearance step documentation.<\/td>\n            <td>Gamma irradiation provides additional assurance against viral contamination in FBS \u2014 relevant for viral vector production where contamination would compromise product safety.<\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- CAR-T PHASE TABLE -->\n  <div class=\"sec\">\n    <h2>CAR-T Manufacturing \u2014 Reagent Requirements by Phase<\/h2>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Phase<\/th><th>Process Step<\/th><th>Recommended Product<\/th><th>Key Note<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td><strong>R&amp;D \u2014 Process Development<\/strong><\/td>\n            <td>T cell isolation, activation screening, vector optimisation<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-ultra-low-igg-low-igg\">FBS Ultra Low IgG &lt;5 \u00b5g\/mL<\/a><\/td>\n            <td>Low IgG prevents FcR competition in T cell activation assays \u2014 cost-effective for high-throughput screening before GMP commitment<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>R&amp;D \u2192 GMP \u2014 T Cell Activation<\/strong><\/td>\n            <td>CD3\/CD28 stimulation, IL-2 supplementation, pre-expansion<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-off-the-clot-type-ab-male\">Human Serum AB OTC Male<\/a> (or HI where complement must be inactivated)<\/td>\n            <td>OTC: maximum platelet growth factors for activation signal amplification. HI: when complement activation during stimulation is problematic.<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>GMP \u2014 Ex Vivo T Cell Expansion<\/strong><\/td>\n            <td>Large-scale CAR-T expansion in static bags or rocker bioreactor<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-off-the-clot-type-ab-male\">Human Serum AB OTC Male<\/a> \u2014 5\u201310%<\/td>\n            <td>EMA\/410\/01 preferred ancillary material. Ph. Eur. 5.2.12 documentation included on request. Batch reservation for full Phase I campaign.<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>GMP \u2014 Bioreactor Expansion<\/strong><\/td>\n            <td>Rocking bag scale-up (0.5\u201350 L)<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/rocker-bags\">Rocker Bags 0.5\u2013200 L<\/a><\/td>\n            <td>Corning and HyPerforma platform compatible. ISO 13485. Gamma sterilised \u226525 kGy ISO 11137. Custom port configurations.<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>GMP \u2014 Xeno-Free \/ Serum-Free Protocols<\/strong><\/td>\n            <td>Defined serum-free T cell expansion medium<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/rec-human-serum-albumin-rec-hsa\/rhsa-premium-grade\">rHSA Premium Grade<\/a> as albumin supplement<\/td>\n            <td>For fully xeno-free GMP protocols. rHSA replaces albumin supplementation with defined, lot-consistent animal-free alternative.<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>GMP \u2014 Media Preparation &amp; Storage<\/strong><\/td>\n            <td>Media preparation, buffer formulation<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/2d-bioprocessing-bags\">2D Single-Use Bags 150 mL\u201350 L<\/a><\/td>\n            <td>Closed system \u2014 no cleaning validation. GMP documentation. Drop-in for Sartorius Flexboy. ISO 13485 Germany.<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>GMP \u2014 Harvest &amp; Formulation<\/strong><\/td>\n            <td>Cell harvest, wash, formulation in cryo medium<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/single-use-bioprocessing\/2d-bioprocessing-bags\">2D Single-Use Bags<\/a> + <a href=\"https:\/\/www.seamlessbio.de\/products\/albumin-proteins\/rec-human-serum-albumin-rec-hsa\/rhsa-premium-grade\">rHSA<\/a> or native HSA in formulation buffer<\/td>\n            <td>Closed transfer into gamma-sterilised bags. HSA\/rHSA as protein stabiliser in formulation buffer \u2014 prevents cell adsorption to surfaces.<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>QC \u2014 Release Testing<\/strong><\/td>\n            <td>Cytotoxicity, ELISpot, ADCC potency assay<\/td>\n            <td><a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-low-very-low-endotoxin\">FBS VLE \u22641 EU\/mL<\/a> + <a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-type-ab-male\">Human Serum AB HI<\/a><\/td>\n            <td>VLE FBS for ELISpot background reduction. Human Serum AB HI for PBMC-based release assays where complement-free matrix required.<\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- SUPPLY CHAIN -->\n  <div class=\"sec\">\n    <h2>ATMP Supply Chain Requirements \u2014 What SeamlessBio Provides<\/h2>\n    <p>ATMP manufacturing has unique supply chain demands that differ fundamentally from research use. A reagent lot change mid-process can invalidate months of process development work and require complete process re-validation.<\/p>\n    <div class=\"tw\">\n      <table>\n        <thead><tr><th>Requirement<\/th><th>SeamlessBio Solution<\/th><th>Regulatory Relevance<\/th><\/tr><\/thead>\n        <tbody>\n          <tr>\n            <td><strong>Batch reservation<\/strong><\/td>\n            <td>Reserve a dedicated lot from process development through clinical manufacturing. Up to 6 weeks cost-free during evaluation; extended reservation for full Phase I\/II campaign on request.<\/td>\n            <td>GMP process validation \u2014 same lot throughout manufacturing campaign required to avoid re-validation<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>Extended lot testing<\/strong><\/td>\n            <td>Mycoplasma, sterility, BVDV, HAV, B19 parvovirus, extended adventitious agent panels available on request through supply network.<\/td>\n            <td>ICH Q5A \u2014 viral safety of biological raw materials in ATMP manufacturing<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>EU origin and EU logistics<\/strong><\/td>\n            <td>EU-sourced human serum from EU Blood Directive-qualified donor centres. Germany-based logistics \u2014 24\u201348 hour cold-chain delivery DACH and EU.<\/td>\n            <td>EMA ATMP submissions: EU-origin material simplifies regulatory documentation vs non-EU-origin<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>Ph. Eur. 5.2.12 documentation<\/strong><\/td>\n            <td>Full Ph. Eur. 5.2.12 declaration for human-derived ancillary materials on request. Eudralex Vol. 4 Part IV compliance documentation.<\/td>\n            <td>Mandatory for human-derived ancillary materials in GMP ATMP Phase I\/II manufacturing<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>No minimum order quantity<\/strong><\/td>\n            <td>100 mL for validation through to bulk volumes for clinical manufacturing \u2014 same supplier, same lot.<\/td>\n            <td>Process consistency from validation scale through clinical scale without supplier change<\/td>\n          <\/tr>\n          <tr>\n            <td><strong>FBS \u2192 Human Serum transition support<\/strong><\/td>\n            <td>Validated stepwise transition protocol: 50% FBS\/50% Human Serum \u2192 25%\/75% \u2192 100% Human Serum over 3 weeks with monitoring parameters.<\/td>\n            <td>EMA\/410\/01 compliance \u2014 transition from FBS-based research process to human serum for clinical manufacturing<\/td>\n          <\/tr>\n        <\/tbody>\n      <\/table>\n    <\/div>\n  <\/div>\n\n  <!-- FAQ -->\n  <div class=\"faq\">\n    <h2>Frequently Asked Questions<\/h2>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Why does FBS Tet-Free matter specifically for CAR-T development?<\/div>\n      <div class=\"faq-a\">Standard FBS contains tetracycline residues at 10\u2013100 ng\/mL from routine antibiotic use in bovine husbandry. Tet-On and Tet-Off inducible gene expression systems \u2014 widely used for inducible CAR construct expression and lentiviral packaging cell lines \u2014 are suppressed by tetracycline at concentrations as low as 1\u201310 ng\/mL. Standard FBS can partially or completely suppress transgene induction in these systems, causing researchers to incorrectly conclude their construct is non-functional. FBS Tet-Free &lt;10 ng\/mL eliminates this interference and is the only correct grade for any Tet-regulated ATMP application.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Can I use standard FBS for Phase I\/II CAR-T trials?<\/div>\n      <div class=\"faq-a\">EMA\/410\/01 discourages FBS in clinical ATMP manufacturing and requires explicit justification if animal-derived ancillary materials are used. For Phase I\/II CTA submissions to EMA, human serum or defined xeno-free media are the expected standard. FBS-based processes will face regulatory questions and may require additional xenogenic sensitisation safety testing documentation. For GMP-phase manufacturing, SeamlessBio recommends transitioning to Human Serum AB OTC Male. Where FBS is still required for non-clinical studies or specific process steps, the FBS grade must be specified \u2014 standard FBS is not acceptable in ATMP contexts.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">What is the difference between hPL and Human Serum for T cell expansion?<\/div>\n      <div class=\"faq-a\">Human Platelet Lysate (hPL) is produced by freeze-thaw lysis of pooled platelets \u2014 it releases a very high concentration of platelet-derived growth factors (PDGF, TGF-\u03b2, FGF, EGF, IGF-1) with no serum immunoglobulins. hPL is particularly effective for MSC expansion (typically 3\u20135\u00d7 higher proliferation rates vs FBS) and has been used in xeno-free T cell expansion protocols. Human Serum AB OTC Male is the established standard for CAR-T T cell expansion \u2014 with extensive clinical validation data. hPL may offer advantages in specific protocols but requires its own process validation. Both are available from SeamlessBio with EU donor documentation.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">How long can I reserve a Human Serum AB OTC Male lot for a CAR-T programme?<\/div>\n      <div class=\"faq-a\">SeamlessBio holds reserved Human Serum AB OTC Male lots for up to 6 months during process development and clinical manufacturing campaigns \u2014 no cost during the evaluation phase, with flexible call-off volumes from 100 mL to bulk. For Phase I autologous CAR-T manufacturing typically requiring 3\u201310 patient batches, a lot reservation of 500 mL to 2 L is usually sufficient. Extended reservation beyond 6 months is available on request for multi-year ATMP development programmes.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Which documentation does SeamlessBio provide for EMA ATMP submissions?<\/div>\n      <div class=\"faq-a\">For Human Serum AB products: CoA, Certificate of Origin (EU Blood Directive-qualified donor centres), viral testing panel per lot (HIV-1\/2 NAT, HBV NAT, HCV NAT, CMV, EBV, Parvovirus B19), Ph. Eur. 5.2.12 declaration on request, and Eudralex Vol. 4 Part IV compliance documentation. For FBS specialty grades: CoA, CoO, TSE\/BSE statement per EMA CHMP\/BWP, mycoplasma testing, BVDV testing, gamma irradiation certificate where applicable. The full documentation package is assembled per lot and provided with each shipment.<\/div>\n    <\/div>\n    <div class=\"faq-item\">\n      <div class=\"faq-q\">Is Human Platelet Lysate (hPL) suitable for clinical-grade MSC expansion?<\/div>\n      <div class=\"faq-a\">Yes \u2014 hPL is EMA-accepted for clinical-grade MSC expansion and is specified in several published GMP protocols for MSC manufacturing. EMA's Committee for Advanced Therapies (CAT) has reviewed hPL as a xeno-free FBS alternative in MSC-based ATMP manufacturing. SeamlessBio supplies hPL from pooled EU donor platelets with full pathogen screening documentation (HIV, HBV, HCV, Parvovirus B19, CMV, EBV) and batch consistency testing. For clinical applications, we recommend requesting lot-specific growth promotion test data alongside the standard CoA.<\/div>\n    <\/div>\n  <\/div>\n\n  <!-- RELATED -->\n  <div class=\"related\">\n    <h3>Related Applications &amp; Products<\/h3>\n    <div class=\"rel-grid\">\n      <a href=\"https:\/\/www.seamlessbio.de\/applications\/car-t-cell-manufacturing\">\u2192 CAR-T Cell Manufacturing \u2014 Full Guide<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/applications\/ipsc-stem-cell-culture\">\u2192 iPSC &amp; Stem Cell Culture Guide<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/applications\/aav-viral-vector-production\">\u2192 AAV &amp; Viral Vector Production<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-serum-off-the-clot-type-ab-male\">\u2192 Human Serum AB OTC Male<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/human-sera-plasma-and-more\/human-platelet-lysate-hpl\">\u2192 Human Platelet Lysate (hPL)<\/a>\n      <a href=\"https:\/\/www.seamlessbio.de\/products\/fetal-bovine-serum\/fbs-tet-free\">\u2192 FBS Tet-Free &lt;10 ng\/mL<\/a>\n    <\/div>\n  <\/div>\n\n  <!-- CTA -->\n  <!-- HUB BACKLINK -->\n  <div style=\"text-align:center;padding:20px 0 0;border-top:1px solid rgba(24,183,178,.15);margin-bottom:16px;\">\n    <a href=\"https:\/\/www.seamlessbio.de\/applications\/\" style=\"display:inline-flex;align-items:center;gap:8px;color:#18b7b2;font-size:14px;font-weight:700;text-decoration:none;\">\n      \u2190 All Application Guides Overview\n    <\/a>\n  <\/div>\n\n  <div class=\"cta\">\n    <h2>Batch Reservation &amp; GMP Documentation for ATMP Programmes<\/h2>\n    <p>Reserve a validated lot of Human Serum AB OTC Male for your full Phase I\/II CAR-T or ATMP programme. Full Ph. Eur. 5.2.12 and Eudralex Vol. 4 Part IV documentation package available. Free test samples for process development. EU cold-chain delivery DACH and EU within 24\u201348 hours.<br>Email: info@seamlessbio.de | +49 851 37932226<\/p>\n    <div class=\"ctabtns\">\n      <a href=\"mailto:info@seamlessbio.de\" class=\"ctab1\">Contact Us<\/a>\n      <a href=\"https:\/\/shop.seamlessbio.de\" class=\"ctab2\">View in Shop<\/a>\n    <\/div>\n  <\/div>\n<\/div>\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"FAQPage\",\n      \"@id\": \"https:\/\/www.seamlessbio.de\/applications\/cell-therapy-atmps#faqpage\",\n      \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Why does FBS Tet-Free matter specifically for CAR-T development?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Standard FBS contains tetracycline residues at 10\u2013100 ng\/mL from routine antibiotic use in bovine husbandry. Tet-On and Tet-Off inducible gene expression systems \u2014 widely used for inducible CAR construct expression and lentiviral packaging cell lines \u2014 are suppressed by tetracycline at concentrations as low as 1\u201310 ng\/mL. Standard FBS can partially or completely suppress transgene induction in these systems, causing researchers to incorrectly conclude their construct is non-functional. FBS Tet-Free &lt;10 ng\/mL eliminates this interference and is the only correct grade for any Tet-regulated ATMP application.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Can I use standard FBS for Phase I\/II CAR-T trials?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"EMA\/410\/01 discourages FBS in clinical ATMP manufacturing and requires explicit justification if animal-derived ancillary materials are used. For Phase I\/II CTA submissions to EMA, human serum or defined xeno-free media are the expected standard. FBS-based processes will face regulatory questions and may require additional xenogenic sensitisation safety testing documentation. For GMP-phase manufacturing, SeamlessBio recommends transitioning to Human Serum AB OTC Male. Where FBS is still required for non-clinical studies or specific process steps, the FBS grade must be specified \u2014 standard FBS is not acceptable in ATMP contexts.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the difference between hPL and Human Serum for T cell expansion?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Human Platelet Lysate (hPL) is produced by freeze-thaw lysis of pooled platelets \u2014 it releases a very high concentration of platelet-derived growth factors (PDGF, TGF-\u03b2, FGF, EGF, IGF-1) with no serum immunoglobulins. hPL is particularly effective for MSC expansion (typically 3\u20135\u00d7 higher proliferation rates vs FBS) and has been used in xeno-free T cell expansion protocols. Human Serum AB OTC Male is the established standard for CAR-T T cell expansion \u2014 with extensive clinical validation data. hPL may offer advantages in specific protocols but requires its own process validation. Both are available from SeamlessBio with EU donor documentation.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How long can I reserve a Human Serum AB OTC Male lot for a CAR-T programme?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"SeamlessBio holds reserved Human Serum AB OTC Male lots for up to 6 months during process development and clinical manufacturing campaigns \u2014 no cost during the evaluation phase, with flexible call-off volumes from 100 mL to bulk. For Phase I autologous CAR-T manufacturing typically requiring 3\u201310 patient batches, a lot reservation of 500 mL to 2 L is usually sufficient. Extended reservation beyond 6 months is available on request for multi-year ATMP development programmes.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Which documentation does SeamlessBio provide for EMA ATMP submissions?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"For Human Serum AB products: CoA, Certificate of Origin (EU Blood Directive-qualified donor centres), viral testing panel per lot (HIV-1\/2 NAT, HBV NAT, HCV NAT, CMV, EBV, Parvovirus B19), Ph. Eur. 5.2.12 declaration on request, and Eudralex Vol. 4 Part IV compliance documentation. For FBS specialty grades: CoA, CoO, TSE\/BSE statement per EMA CHMP\/BWP, mycoplasma testing, BVDV testing, gamma irradiation certificate where applicable. The full documentation package is assembled per lot and provided with each shipment.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Human Platelet Lysate (hPL) suitable for clinical-grade MSC expansion?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes \u2014 hPL is EMA-accepted for clinical-grade MSC expansion and is specified in several published GMP protocols for MSC manufacturing. EMA's Committee for Advanced Therapies (CAT) has reviewed hPL as a xeno-free FBS alternative in MSC-based ATMP manufacturing. SeamlessBio supplies hPL from pooled EU donor platelets with full pathogen screening documentation (HIV, HBV, HCV, Parvovirus B19, CMV, EBV) and batch consistency testing. For clinical applications, we recommend requesting lot-specific growth promotion test data alongside the standard CoA.\"\n      }\n    }\n      ]\n    },\n    {\n      \"@type\": \"BreadcrumbList\",\n      \"@id\": \"https:\/\/www.seamlessbio.de\/applications\/cell-therapy-atmps#breadcrumb\",\n      \"itemListElement\": [\n        {\n          \"@type\": \"ListItem\",\n          \"position\": 1,\n          \"name\": \"Home\",\n          \"item\": \"https:\/\/www.seamlessbio.de\/\"\n        },\n        {\n          \"@type\": \"ListItem\",\n          \"position\": 2,\n          \"name\": \"Applications\",\n          \"item\": \"https:\/\/www.seamlessbio.de\/applications\/\"\n        },\n        {\n          \"@type\": \"ListItem\",\n          \"position\": 3,\n          \"name\": \"Cell Therapy & ATMPs\",\n          \"item\": \"https:\/\/www.seamlessbio.de\/applications\/cell-therapy-atmps\"\n        }\n      ]\n    }\n  ]\n}\n<\/script>\n<\/section>\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Home\/ Applications\/ Cell Therapy &amp; ATMP Manufacturing SeamlessBio \u2014 Solutions by Application Cell Therapy &amp; ATMP Manufacturing \u2014 FBS, Human Serum &amp; hPL Supply Guide Advanced therapy medicinal products \u2014 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_eb_attr":"","footnotes":""},"class_list":["post-695","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cell Therapy &amp; ATMP Manufacturing \u2014 hPL, Human Serum AB<\/title>\n<meta name=\"description\" content=\"Human Platelet Lysate, Human Serum AB Male OTC and rHSA for ATMP manufacturing. Xeno-free protocols, EMA documentation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlessbio.de\/de\/biopharma-atmp\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cell Therapy &amp; ATMP Manufacturing \u2014 hPL, Human Serum AB\" \/>\n<meta property=\"og:description\" content=\"Human Platelet Lysate, Human Serum AB Male OTC and rHSA for ATMP manufacturing. Xeno-free protocols, EMA documentation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/seamlessbio.de\/de\/biopharma-atmp\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-27T11:09:09+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"10\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/biopharma-atmp\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/biopharma-atmp\\\/\",\"name\":\"Cell Therapy & ATMP Manufacturing \u2014 hPL, Human Serum AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-05-14T15:20:41+00:00\",\"dateModified\":\"2026-06-27T11:09:09+00:00\",\"description\":\"Human Platelet Lysate, Human Serum AB Male OTC and rHSA for ATMP manufacturing. Xeno-free protocols, EMA documentation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/biopharma-atmp\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/biopharma-atmp\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/biopharma-atmp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/seamlessbio.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Application Cell Therapy &amp; ATMP Manufacturing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Expert for biological materials for pharma, vaccines and research organizations\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"width\":309,\"height\":88,\"caption\":\"SeamlessBio\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cell Therapy & ATMP Manufacturing \u2014 hPL, Human Serum AB","description":"Human Platelet Lysate, Human Serum AB Male OTC and rHSA for ATMP manufacturing. Xeno-free protocols, EMA documentation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlessbio.de\/de\/biopharma-atmp\/","og_locale":"de_DE","og_type":"article","og_title":"Cell Therapy & ATMP Manufacturing \u2014 hPL, Human Serum AB","og_description":"Human Platelet Lysate, Human Serum AB Male OTC and rHSA for ATMP manufacturing. Xeno-free protocols, EMA documentation.","og_url":"https:\/\/seamlessbio.de\/de\/biopharma-atmp\/","og_site_name":"SeamlessBio","article_modified_time":"2026-06-27T11:09:09+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"10\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/seamlessbio.de\/biopharma-atmp\/","url":"https:\/\/seamlessbio.de\/biopharma-atmp\/","name":"Cell Therapy & ATMP Manufacturing \u2014 hPL, Human Serum AB","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-05-14T15:20:41+00:00","dateModified":"2026-06-27T11:09:09+00:00","description":"Human Platelet Lysate, Human Serum AB Male OTC and rHSA for ATMP manufacturing. Xeno-free protocols, EMA documentation.","breadcrumb":{"@id":"https:\/\/seamlessbio.de\/biopharma-atmp\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlessbio.de\/biopharma-atmp\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/seamlessbio.de\/biopharma-atmp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/seamlessbio.de\/"},{"@type":"ListItem","position":2,"name":"Application Cell Therapy &amp; ATMP Manufacturing"}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Experte f\u00fcr biologische Materialien f\u00fcr die Pharmaindustrie, Impfstoffe und Forschungseinrichtungen","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/#\/schema\/logo\/image\/","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","width":309,"height":88,"caption":"SeamlessBio"},"image":{"@id":"https:\/\/seamlessbio.de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=695"}],"version-history":[{"count":8,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/695\/revisions"}],"predecessor-version":[{"id":1812,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/695\/revisions\/1812"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}